Plain-English translation of NCT06345365 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a newer chemotherapy combination called MA+AZA (which includes mitoxantrone liposome, cytarabine, and azacitidine) against a standard chemotherapy combination called DA+AZA (which includes daunorubicin, cytarabine, and azacitidine) in people newly diagnosed with acute myeloid leukemia. The goal is to find out whether this medication works better than or as well as the traditional treatment.
Acute myeloid leukemia is a serious blood cancer, and doctors want to improve how well they can treat it. This medication may be more effective or safer than older chemotherapy regimens, and this study will provide evidence to help improve treatment options for future patients.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will be randomly assigned to receive one of the two chemotherapy combinations. You will receive intravenous (IV) infusions and injections over a week-long treatment cycle, with the IV chemotherapy given every 4 weeks. You will need to visit the hospital regularly for treatment, blood tests, and monitoring of how well the medication is working and any side effects you experience.
AI-generated summary from trial data ยท Aug 5, 2026 ยท Not medical advice
China